MX2017002790A - Sal de un derivado de cefalosporina, forma solida cristalina del mismo y metodo para su produccion. - Google Patents
Sal de un derivado de cefalosporina, forma solida cristalina del mismo y metodo para su produccion.Info
- Publication number
- MX2017002790A MX2017002790A MX2017002790A MX2017002790A MX2017002790A MX 2017002790 A MX2017002790 A MX 2017002790A MX 2017002790 A MX2017002790 A MX 2017002790A MX 2017002790 A MX2017002790 A MX 2017002790A MX 2017002790 A MX2017002790 A MX 2017002790A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- same
- solid form
- crystalline solid
- cephalosporin derivative
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- 239000007787 solid Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229930186147 Cephalosporin Natural products 0.000 title 1
- 229940124587 cephalosporin Drugs 0.000 title 1
- 150000001780 cephalosporins Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
- C07D227/02—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D227/06—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona una sal de adición ácida o una sal de sodio de un compuesto representado por la fórmula (IA), o su hidrato de la sal o una forma sólida cristalina estable de la sal. La sal o la forma sólida cristalina de la misma, es extremadamente útil como un ingrediente activo para la producción de un producto farmacéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014179853 | 2014-09-04 | ||
| PCT/JP2015/075039 WO2016035845A1 (ja) | 2014-09-04 | 2015-09-03 | セファロスポリン誘導体の塩、その結晶性固体およびその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017002790A true MX2017002790A (es) | 2017-05-30 |
| MX377314B MX377314B (es) | 2025-03-07 |
Family
ID=55439902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002790A MX377314B (es) | 2014-09-04 | 2015-09-03 | Sal de un derivado de cefalosporina, forma sólida cristalina del mismo y método para su producción. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10004750B2 (es) |
| EP (1) | EP3190115B1 (es) |
| JP (1) | JP6120429B2 (es) |
| KR (2) | KR102284990B1 (es) |
| CN (1) | CN106795176B (es) |
| AU (1) | AU2015312828B2 (es) |
| BR (1) | BR112017004166B1 (es) |
| CA (1) | CA2959295C (es) |
| CY (1) | CY1124838T1 (es) |
| DK (1) | DK3190115T3 (es) |
| EA (1) | EA035845B1 (es) |
| ES (1) | ES2893424T3 (es) |
| HR (1) | HRP20211524T1 (es) |
| HU (1) | HUE056038T2 (es) |
| LT (1) | LT3190115T (es) |
| MA (1) | MA40585A (es) |
| MX (1) | MX377314B (es) |
| MY (1) | MY178017A (es) |
| PH (1) | PH12017500435B1 (es) |
| PL (1) | PL3190115T3 (es) |
| PT (1) | PT3190115T (es) |
| RS (1) | RS62449B1 (es) |
| SI (1) | SI3190115T1 (es) |
| SM (1) | SMT202100584T1 (es) |
| TW (1) | TWI593690B (es) |
| WO (1) | WO2016035845A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3471724A1 (en) * | 2016-06-17 | 2019-04-24 | Wockhardt Limited | Antibacterial compositions |
| WO2020184399A1 (ja) * | 2019-03-08 | 2020-09-17 | 塩野義製薬株式会社 | 抗菌用医薬組成物 |
| TW202220663A (zh) | 2020-07-28 | 2022-06-01 | 日商鹽野義製藥股份有限公司 | 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591728A (en) * | 2008-10-31 | 2012-12-21 | Shionogi & Co | Cephalosporin having catechol group |
| IN2012CN09242A (es) | 2010-04-05 | 2015-08-21 | Shionogi & Co | |
| UY35103A (es) * | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| EP3189841B1 (en) * | 2014-09-04 | 2023-11-22 | Shionogi & Co., Ltd. | Pharmaceutical preparation comprising cephalosporin having catechol groups |
-
2015
- 2015-09-03 WO PCT/JP2015/075039 patent/WO2016035845A1/ja not_active Ceased
- 2015-09-03 AU AU2015312828A patent/AU2015312828B2/en active Active
- 2015-09-03 US US15/508,270 patent/US10004750B2/en active Active
- 2015-09-03 SI SI201531718T patent/SI3190115T1/sl unknown
- 2015-09-03 KR KR1020187021768A patent/KR102284990B1/ko active Active
- 2015-09-03 PH PH1/2017/500435A patent/PH12017500435B1/en unknown
- 2015-09-03 RS RS20211278A patent/RS62449B1/sr unknown
- 2015-09-03 HU HUE15838484A patent/HUE056038T2/hu unknown
- 2015-09-03 EA EA201790522A patent/EA035845B1/ru unknown
- 2015-09-03 ES ES15838484T patent/ES2893424T3/es active Active
- 2015-09-03 PT PT158384842T patent/PT3190115T/pt unknown
- 2015-09-03 DK DK15838484.2T patent/DK3190115T3/da active
- 2015-09-03 CA CA2959295A patent/CA2959295C/en active Active
- 2015-09-03 SM SM20210584T patent/SMT202100584T1/it unknown
- 2015-09-03 PL PL15838484T patent/PL3190115T3/pl unknown
- 2015-09-03 BR BR112017004166-9A patent/BR112017004166B1/pt active IP Right Grant
- 2015-09-03 KR KR1020177008727A patent/KR20170043663A/ko not_active Ceased
- 2015-09-03 CN CN201580047079.6A patent/CN106795176B/zh active Active
- 2015-09-03 JP JP2016546687A patent/JP6120429B2/ja active Active
- 2015-09-03 HR HRP20211524TT patent/HRP20211524T1/hr unknown
- 2015-09-03 EP EP15838484.2A patent/EP3190115B1/en active Active
- 2015-09-03 LT LTEPPCT/JP2015/075039T patent/LT3190115T/lt unknown
- 2015-09-03 MX MX2017002790A patent/MX377314B/es active IP Right Grant
- 2015-09-03 MA MA040585A patent/MA40585A/fr unknown
- 2015-09-03 MY MYPI2017700556A patent/MY178017A/en unknown
- 2015-09-04 TW TW104129406A patent/TWI593690B/zh active
-
2021
- 2021-10-21 CY CY20211100921T patent/CY1124838T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| MX2017001980A (es) | Derivado de quinolina muy puro y metodo para su produccion. | |
| TN2017000204A1 (en) | Triazolopyrimidine compounds and uses thereof | |
| NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
| MX2017001620A (es) | Formas cristalinas de inhibidores de glutaminasa. | |
| PH12015501752A1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| MY178371A (en) | Pharmaceutical preparation | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| WO2015142903A3 (en) | Method of controlling lactate production with piperdine-dione derivatives | |
| EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
| HK1199025A1 (en) | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| MX2017006200A (es) | Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. | |
| MY185367A (en) | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof | |
| CY1124838T1 (el) | Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου | |
| EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| AU2015280874A1 (en) | Novel heterocyclic compound | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| ECSP13012365A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, | |
| HK1212978A1 (zh) | 芥子酸的新型衍生物 | |
| SG10201901578UA (en) | Processes for the preparation of pyrimidinylcyclopentane compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |